ConferenCe

ww

w.fl

emin

g.ev

ents

11th A

nnua

l

Taking patient centricity and investment efficiency a step further

February 21 - 22, 2018 Philadelphia, PA

Project & Portfolio Management for Pharma and Biotech Summit East Coast

Co-located with the 5th Pharmacovigilance and RMS Forum

www.fleming.events

Expert Speakers and Panelists Sultan AzizJohnson & JohnsonHead of Product Supply Strategy Management

Michael Myerseli LillySenior Director, Global external r&D

Sean XueTakedaDirector of Portfolio Analytics, Global r&D Portfolio Management

Lena R. Frankeisaiexecutive Director, Alliance & Program Management

Ricky SuchakSandozDirector, Head of Portfolio Management and Marketing

Usman IqbalTrevenaSenior Director, Medical Affairs & Heor

Audrey Echertier-BonnardGSKPortfolio & Project Management Director, Consumer Healthcare

Chris DandreaSanofi GenzymeHead of Project Management Group, oncology Development

Lena Ohannesian Ph.D.Teva PharmaceuticalsSenior Director, Project Champion

Varsha ChhatreBristol-Myers SquibbAssociate Director, Planning & execution Lead

Kurt Nielsen, Ph.D.SandozVice President, US Development, Portfolio and Launch Management

Heather GaylordShireAssociate Director & Lead, Portfolio Management & reporting

Pik Leng WongSanofi GenzymeDirector, Biologics Project Management office (PMo)

Christopher BeckAevi Genomic MedicineVice President, Program Management

Christopher LarsonAllerganDirector, Portfolio Management

Knowledge Partner

email: registrations@fleming.events

Co-located events - Ensuring you get more value

Welcome back! Dear Industry Colleagues,Building on the experience of 10 previous events, this PPM Summit will focus on introducing the best ways forward in enhanced r&D productivity, resource management, unbiased decision making and PPM excellence.

This event will be held over two intensive days full of real insight sharing, problem solving and networking opportunities.

The 11th Project & Portfolio Management for Pharma and Biotech Summit - east Coast will be co-located with the 5th Pharmacovigilance and risk Management Strategies forum, so as to ensure maximized learning and networking opportunities.

We look forward to welcoming you in february!

Who Will AttendThe Project & Portfolio Management for Pharma and Biotech Conference Series attract senior level executives and corporate decision-makers from around the world including Chairmen, CEOs, CFOs, Presidents and Managing Directors from: pharmaceutical and biotechnology companies, medical device, medical technology, instrumentation and diagnostics companies,

as well as

Pharmaceutical and biotech industry professionals involved in:

Portfolio Management

Project Management

r&D Management

Pipeline Planning

resource Planning

Asset Management

Alliance Management

Program Management

Lifecycle Management

Product Management

finance

risk Management

Job Title Distribution

34% Cxos, VPs

18% Directors, Heads

12% Senior Management

www.fleming.events

More Than A Decade Of Pharma Ppm Conferences

Rome

Milan

Barcelona

Vienna

Berlin

Frankfurt

Boston

Atlantic City

San Francisco

Philadelphia

2004

2017

overall satisfaction rate

of attendees would recommend

the event to their colleagues

89%

93%What Last Year's Attendees Say...“The conference was well organized with very good speakers and topics.

The opportunity for interactive sessions was excellent and the structured networking at the lunch break was greatly appreciated!”

Vice President, Program Leadership, Aegerion Pharmaceuticals, Chair of BioPharmaPM Group

"Good mix of topics and great networking event!" Senior Director, R&D Analytics, Janssen, J&J

“Good conference. Very thought-provoking topics and presentations.”CEO, Drais Pharmaceuticals

"Nice lineup of speakers and topics, thus a great insight for a newcomer to the field!"

Senior Scientist, AbbVie

“I appreciated the size of the conference - small enough to enable sharing of ideas in a trusting environment, large enough to be representative of the industry”

Director, Pfizer

"Excellent agenda. Engaging speakers & sessions!"Director of Project Management, Sucampo

“This conference gave a great overview of the challenges facing the industry whether a small company or a large company.”

Associate Director, Project Operations, Novavax

"Great topics and networking opportunities."Project Manager, Eli Lilly

“An excellent, focused conference, and great opportunity to network across the industry.”

Associate Director, Novavax

“Very interactive sessions with useful new tips and advice throughout.”SVP Portfolio Planning, BTG Pharmaceuticals

“Really great conference. Very focused and relevant!”Associate Director, Project Management, Novavax

“An informative conference. Compelling information & experience sharing with lots of networking chance. Will attend next year. Thank you!”

Director, Project Management, Lumosa Therapeutics

email: registrations@fleming.events

www.fleming.events

DAY 1february 21, 2018

8:00 Coffee & Registration

8:45 Welcome Note by Fleming.

9:00 Chairperson's Opening Remarks

9:10 Opening Plenary Session:

C-level PPM Vision and the Driving forces of Transformation

9: 50 Best Practice Panel: Prioritization Elements for Success – Doing the Right Work at All Possible Times

•r&D Goal Setting & Measuring •Benefits-Led Portfolio Management - Maximizing

Investment returns•Managing Projects within a Portfolio - essential

elements to reduce failure •Strengthened Decision Making Using a Business

Case Writing&review Process•How Teams Develop Asset Strategy (vs. TA

Strategy or Portfolio Strategy)•TA-Specific Drug Development

Heather Gaylord, Shire, Associate Director & Lead, Portfolio Management & Reporting

Ricky Suchak, Sandoz, Director, Head of Portfolio Management and Marketing

10:30 Networking & Energizer Break

11:00 sPotlight session: Dynamics of a High-Performing Cross-Functional Global Team - Preparedness for High-Level Regulatory Interactions

•How to build and manage a high-performing cross-functional team across borders

•facing uncertain times and different regulatory agencies' expectations

•Preparing the core team for high-level regulatory interactions – What tactics to use

Lena Ohannesian Ph.D., Teva PharmaceuticalsSenior Director, Project Champion

11:30 Best Practice Panel: Principles of Global Operations

•Portfolio Management in a Global Setting•risk Management in a Global Setting•Global Program Teams: who is on it, how is it

formed, what are the key principles•Global Team Management

12:10 Networking Lunch

2:00 sPotlight session: Going Beyond Risk & Return – The R&D Perspective

•What is real innovation in medicine?•More dimensions than financial and commercial •Value in a much broader sense – Going beyond

nPV with your r&D portfolio strategy•Addressing phase transition risk, safety risk,

market risk, commercial risk

Sean Xue, Takeda, Director of Portfolio Analytics, Global R&D Portfolio Management

email: registrations@fleming.events

www.fleming.events

DAY 1february 21, 2018

2:40 sPotlight session: The R&D Perspective Through Real World Lens

•Innovation: Pure science vs. delivering on patient needs

•need for assessment of Portfolio Value through the lens of reality – Concept of Medical Value that iteratively drives the portfolio strategy in today’s value and cost conscious environment

•A medical value based model to address TPP and risk mitigation in early r&D – focus on a bottom-up approach with asset strategy to TA & Portfolio Strategy

•refinement of acumen, skills and competencies for Portfolio managers to differentiate themselves from the competition

Usman Iqbal, Trevena, Senior Director, Medical Affairs & HEOR

3:20 Networking Coffee

3:50 sPotlight session: Scaling Up Innovation

•How we think about the concept of innovation•J&J Innovation Centers across the world – How

they accelerate the best early-stage science in the world and advance the development of new healthcare solutions

•How do you scale up innovation - Is it research or manufacturing

•Key capabilities of accelerating innovation•examining the reasons why large pharma

companies end up with less innovative products

Sultan Aziz, Johnson & Johnson, Head of Product Supply Strategy Management

4:20 case stUDY: Leading a Change Program on GSK's Innovation Process

•Innovation process or the challenge to think global and act local

•Story of an improvement journey•Identifying key milestones and main learnings

to bring back to your organization

Audrey Echertier-Bonnard, GSK, Portfolio & Project Management Director, Consumer Healthcare

4:50 Best Practice Panel: continuous improvement of the Project Management office

•Managing the Project Management office as a Business Process

•PMo Implementation and the Secrets behind Leading a PMo

•Utilizing enterprise PMos to enable organizational Portfolio Management

•A PMo Maturity Journey•How to Become the Cfo of Your Portfolios?•A PMo's role in organizational Transformations,

Mergers & Acquisitions

Pik Leng Wong, Sanofi Genzyme, Director, Biologics Project Management Office (PMO)

5:10 Interactive Wrap-up Session

5:40 Chairperson's Closing Remarks

6:00 Networking Cocktail Reception

After the sessions of Day 1 conclude, all attendees of the 2 co-located summits are welcome to the Cocktail Reception, held within the networking exhibition area.

Discuss presentations of the day and catch up with speakers and industry peers!

email: registrations@fleming.events

www.fleming.events

DAY 2february 22, 2018

8:00 Coffee & Registration

9:00 Recap of Day 1 and Chairperson's Opening

Essentials of Going from Strategy to Execution

9:10 KicKoff session: The Methodology Makeover – Practical Approach to Transform your Methodology from Inhibitor to Enabler

•PPM Analysis: A Method to Identify and Implement Improvement Potentials on an organizational Level

•Driving results through Advanced Program Delivery and Insight – Perspectives from a Program Performance Center

•regulatory strategies and alternate pathways for earlier commercial launch

9:50 sPotlight session: Strategy to Execution from the PM Perspective

•Influencing and providing info to key decision-makers

•ensuring that your strategy scenarios are planned out well and executed well

Christopher Beck, Aevi Genomic Medicine, Vice President, Program Management

10:30 Networking & Energizer Break

11:00 Best Practice Panel: Portfolio Management in the Face of Declining Budgets

•effects of re-prioritizing and stopping programs in the face of poor results or declining budgets

•Connecting the Dots between Project – Portfolio – Strategy

11:40 Panel of sUccess & failUre stories: Tools that Work

•resource Management Tools •finance & Budget Tools•Tools of Metrics: Dashboards for the Portfolio

of Projects•Best Practice for Tool&Template Creation

– Pros&Cons

12:30 Networking Lunch

2:00 sPotlight session: Essentials of Service Provider PM

•Hypothetical example of Working with a Contract Manufacturer

•Staffing and Positioning •Stakeholder Management•Specifics of Collaborations

2:30 IN-CONFERENCE WORKSHOP: Where is Your Gap? Aligning Projects to Strategy

Workshop participants will have the opportunity to communicate their productivity gaps and learn as a team how to implement efficiency systems to increase project success rates, decrease overall costs, optimize productivity levels, create standardized delivery models, and adapt their project portfolio demands.

*All our attendees have the option of registering for 16 PDUs for the conference attendance, and earn 2 PDUs for the workshop attendance

Kurt Nielsen, Ph.D., Sandoz, Vice President, US Development, Portfolio and Launch Management

4:00 Chairperson's Closing Remarks

4:10 Wrap-Up Session with Farewell Drinks

email: registrations@fleming.events

www.fleming.events

Usman IqbalTrevenaSenior Director, Medical Affairs & Heor

Usman Iqbal MD, MPH, MBA is a Senior Director, Medical Affairs & Heor at Trevena, Inc. Usman has 12+ years of diverse experience spanning clinical medicine, r&D/Med Aff, Health economics & outcomes research across academia and biopharmaceutical. His experience spans number of different therapeutic areas including neuroscience, as Senior Medical Affairs Leader at AstraZeneca, and oncology, as former Head of Sanofi oncology, Global evidence & Value Development (GeVD). As part of both r&D and Med Affairs in different hybrid roles, Usman has had been responsible for Portfolio Prioritizations, Integrated Medical Affairs Planning, and end-to-end evidence generation based on Stakeholder engagement (Patient, Provider, Payer), Market insights and relative Medical Value Assessment Platforms. Prior to working in the industry that also includes Amgen and Boehringer Ingelheim, Usman was at the Boston University Health outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare &, Medicaid Services’ Health outcomes Survey Initiative (CMS-HoS), the Agency for Healthcare research and Quality (AHrQ), and the national Committee for Quality Assurance (nCQA). Usman has authored more than 50 publications and his research experience encompasses patient & physician evaluations in BIG Data and large integrated health care systems with a specific focus on comparative effectiveness, disease management, physician profiling, and patient access solutions.

Michael Myerseli LillySenior Director, Global external r&D

Dr. Mike Myers has spent nearly 30 years in the pharma industry contributing to the discovery and development of new drugs.  He has led drug discovery teams in the pursuit of innovative treatments for cancer, CnS, Infectious and cardiovascular diseases.  Across these areas of significant need, Dr. Myers has contributed as an inventor on more than 35 patents.   Dr. Myers has also led efforts in evaluating new lead generation technologies, predictive ADMeT and computational chemistry approaches and led a significant effort at Lilly to optimize Lead generation processes in early drug discovery.   Dr. Myers has also held responsibilities as Sr. Director of Project Management and was engaged in project and portfolio management across Discovery and Development.  for the last ~9 years, Mike’s main responsibilities within the external Innovation team at eli Lilly & Company includes leading scientific & technical Due Diligence activities in support of in-license/acquisition, out-license and strategic partnering activities.  In addition, for the last several years Dr. Myers has also been very involved in Lilly’s academic outreach by participating in external panel reviews for translational research (The rockefeller Univ., Wash. U., oSU and others) by representing Lilly on Industrial Advisory Boards (e.g, the Univ. of Texas system) and has been working in partnership with several of Lilly’s strategic VC partners in reviewing potential academic sourced opportunities leading to the creation of new companies.

Sultan AzizJohnson & JohnsonHead of Product Supply Strategy Management

Sultan Aziz is a finance executive with broad range of expertise in financial planning & analysis, financial management, mergers and acquisitions (M&A), cost accounting, auditing and capital planning. Sultan is a demonstrated leader, with hands-on experience managing and leading global organizations, broadly recognized for excellent collaboration, communication and team building. He is recognized for integrating business acumen and financial and process knowledge to develop strategies to solve business challenges and drive operating performance. His specialties are financial Planning & Analysis, Budget Management

Licensing & Acquisitions and Divestitures, Business operations, Project Management, Capital Planning & Management, Business Process Improvement, Global Strategic Planning and Change Management.

Lena R. Frankeisaiexecutive Director, Alliance & Program Management

Lena frank is the executive Director of Alliance and Program Management in eisai’s oncology Product Creation Unit. Before joining eisai in 2014, Lena held positions of increasing responsibility with Acorda Therapeutics, Alpharma and rhone-Poulenc. Her past experience includes business development, project and portfolio management, marketing, product management, and sales. Throughout this work experience she has managed various joint ventures, alliances, and licensing relationships, resulting in more than 15 years of experience with alliances. over the past 20 years, Lena has also managed a wide variety of projects and programs ranging from drug development to supply chain optimization to the transition of products into and out of various companies. In addition to being a Certified Strategic Alliance Professional, Lena also holds Project Management Professional certification.

Ricky SuchakSandozDirector, Head of Portfolio Management and Marketing

ricky Suchak is a result oriented professional with progressive experience in Commercial operations, Marketing, Portfolio Management, Business Development & Licensing and Product Development

He has proven leadership, stakeholder management and execution capabilities in cross-functional roles. ricky has a track record of growing business, building high performing teams and processes that improve business efficiencies. He is proficient in navigating fast-moving business environment while successfully performing continuous re-prioritization and executing pragmatic business solutions to achieve targets.

ricky has special expertise in generic and branded pharmaceuticals.

Meet Our Expert Speakers

email: registrations@fleming.events

www.fleming.events

Chris DandreaSanofi GenzymeHead of Project Management Group, oncology Development

Chris Dandrea is a 23 year veteran in the Life Sciences industry with a focus on Drug Development and Commercialization. His current role is Head of Project Management for Sanofi’s oncology Development Portfolio focuses on the creation of a next generation project management organization to help drive rapid patient access to the innovative drug programs in the growing Sanofi oncology Portfolio. Previous role was as Global Project Head within Sanofi-Genzyme’s rare Disease Therapeutic Area covering a spectrum of duties including Phase 3 Development Program Leadership, Marketed Product Life Cycle Management and Portfolio Management to drive future growth. Also at Genzyme, Chris drove the operational Launch of Myozyme®/Lumizyme® for Pompe Disease and Design/Implementation of the Pompe Disease registry. Prior to Genzyme, Chris was a Management Consultant with PrTM’s (now PWC) Life Sciences Industry Group, a field Service engineer with Haemonetics and an officer in the US navy. education includes degrees in electrical and Biomedical engineering from Duke University and an MBA from Carnegie Mellon University.

Lena Ohannesian Ph.D.Teva PharmaceuticalsSenior Director, Project Champion

Dr. Lena ohanessian is a pharmaceutical professional with over 25 years of experience in developing drugs in various sectors of the pharmaceutical industry. She received her Ph.D. in chemistry from the University of Southern California under the advisement of Professor George olah the nobel Laureate in 1994. Having worked for the national Institutes of Health (nIH) and many of the world’s leading companies, including Johnson & Johnson, Janssen Pharmaceutical, and forest Labs. in a number of therapeutic areas, her life’s work has helped bring some of the most groundbreaking therapeutic agents to patients (e.g. Velcade™, Saphris™, Imodium™, Motrin™ and many others). She is the author of a number of publications including a book and has a number of patents. Currently at Teva Specialty Pharmaceutical Medicine she is leading the development of new drugs in the Central nervous System (CnS) and neurology therapeutic area.

email: registrations@fleming.events

Darius Slavik | MD, Corporate Learning Programs

T: +421 257 272 180 | M: +421 918 447 166

CONTACT US TO GET STARTED

APPLY! Get the real ROI by achieving the highest implementation rate of your learning

CUSTOMIZE!in the privacy of your organization

ENGAGE! Make your onboarding and training count with our interactive e-learning programs

This one’s

for you

Why choose our corporate learning programs

Only

CORPORATE LEARNING

In-houseTraining

BlendedLearning e-Learning

Custom Content

e- Learning

Complex Learning Experience

terms and conditions:1. PAYMenT TerMS: AL Conference Production Ltd. (AL) requires the full payment of the invoiced amount within 7 working days from the issue

date of the invoice. AL reserves the right to refuse entry to any client who has not paid its invoice. The registration fee includes: conference documentation, admission to all conference sessions, lunches and refreshments, admission to networking social events. The registration fee does not include: travel, hotel accommodation, transfers or insurance.

2. HoTeL ACCoMMoDATIon: overnight accommodation is not included in the registration fee. A reduced rate may be available at the hotel hosting the event. The reservation form will be sent to the client after the venue has beenc onfirmed, but no later than one month before the event begins.

3. CAnCeLLATIon BY CLIenT: The client has the right to cancel his/her participation in the event. Cancellation must be received by AL in writing, either by mail or fax. If the client cancels with more than one month’s advance notice before the start of the event, AL shall be entitled to retain and charge 50% of the amount payable for participation in the event. If the client cancels with one month’s (or less) advance notice, or fails to attend the event, then the client shall not be entitled to any refund. failure to attend an event shall not excuse a client from owing the full amount of the registration fee. A copy of the conference notes from the event will be sent to the client after the event is over in case of cancellation by the client.

4. CAnCeLLATIon BY AL: While every reasonable effort is made to adhere to the advertised program, circumstances can arise which may cause changes in the program, including but not limited to changes in the content, date(s), location or venue, or special features of the planned event. Such circumstances include but are not limited to acts of terrorism, war, extreme weather conditions, compliance with government requests, orders and legal requirements, failure of third party suppliers to timely deliver, and failure to register the minimum target amount of attendees for a given event. AL reserves the right to change the content, date(s), location or venue and /or special features of an event, to merge the event with another event, or to postpone it or cancel it entirely as appropriate under the circumstances. Client agrees that AL shall not be liable for any cost, damage or expense which may be incurred by client as a consequence of the event being so changed, merged, postponed or cancelled and client agrees to hold AL harmless and to indemnify AL in case of liability caused by any such changes, mergers, postponements or cancellations.

5. CAnCeLLATIon of THe eVenT: In case AL cancels an event, then AL may offer the client a full credit up to the amount actually paid by the client to AL. This credit shall be valid for up to one year from the issue date of the invoice to attend any AL-sponsored events. The client shall not be entitled to this credit as a contractual right.

6. CLIenT’S IDenTIfICATIon InforMATIon. By signing of this sales contract and these terms and conditions the client gives full right to AL to share the client’s identification information such as, but not limited to, client’s name, address, email addresses, phone numbers and names of representatives with third parties, which participated on the same event as the client.

7. JUrISDICTIon: This contract shall be governed and construed in accordance with Illinois Law (not including its conflict of laws provisions AL and the client agree that, any dispute in any way arising out of or relating to this contract will be resolved by arbitration using one arbitrator before JAMS or American Arbitration Association in Chicago, Illinois, USA. The parties to this agreement agree that in any arbitration proceeding they may conduct reasonable discovery pursuant to the arbitration rules, that he law of the state Illinois will be the governing law, and any arbitration award will be enforceable in state or federal court.

8. DISPUTeS InVoLVInG CreDIT CArD PAYMenTS: As a condition of AL agreeing to accept your credit card as a approved form of payment, you especially agree to waive any rights you may have under applicable state and federal truth in lending laws or otherwise (including, but not limited to, under your credit’s card issuer’s procedures for resolving such disputed) to receive a temporary credit from your credit card issuer for disputed charges arising from your credit card transaction with AL (commonly referred to as a “charge back”). You agree that any dispute that may arise with respect to any credit card transaction must be addressed directly between you and us and to work in good faith to resolve any such disputed invoices in timely manner. Any dispute that can not be timely resolved to the mutual satisfaction of the parties shall be resolved in accordance with the dispute resolution provisions as contained in this Agreement.

9. CoLLeCTIon/ATTorneY’S feeS: The parties agree that in the event that any dispute arises in any way relating to or arising out of this Agreement, the prevailing party in any arbitration or court proceeding will be entitled to recover an award of its attorney’s fees and costs, plus pre and post judgment interest. If we retain the services of a collection agency or attorney to assist in the collection of any amounts due to us under this Agreement, you will pay all expenses incurred by us in such collection efforts.

10. InDeMnIfICATIon: To the fullest extent permitted by the law, you agree to protect, indemnify, defend and hold harmless AL, its owners, managers, partners, subsidiaries, affiliates, officers, directors, employees and agents, from and against any and all claims, losses or damages to persons or property, governmental charges or fines, penalties, and costs (including reasonable attorney’s fees) (collectively “the Claims”), in any way arising out of or relating to the event that is the subject of this contract, and regardless of negligence, included but not limited to, Claims arising out of the negligence, gross negligence or intentional misconduct of AL employees, agents, contractors, and attendees; provided, however, that nothing in this indemnification shall require you to indemnify AL Indemnified parties for that portion of any Claim arising out of the sole negligence, gross negligence or intentional misconduct of the AL parties.

11. oTHer ConDITIonS: Any terms or conditions contained in the client’s acceptance which contradict or are different from the terms and conditions of this registration document shall not become part of the contract unless individually negotiated with AL and expressly accepted by AL.

11th Annual Project & Portfolio Management for Pharma and Biotech Summit East Coastfebruary 21 - 22, 2018 | Philadelphia, PA

32 USD administration charge and any applicable withholding or any other tax or fee will be applied

Payment is required within 7 working days

Code: AL LS 31_M

PLEASE COMPLETE THIS FORM AND SEND IT BACK TO:

PH O N E: 312 582 427 7

E-MAIL TO: registrations@fleming.events

OR FAX: 312 674 7304

Client Identification Details(Details to be used on name badges)

Ms Mrs Mr

Name:

Job Title:

Email:

Ms Mrs Mr

Name:

Job Title:

Email:

Ms Mrs Mr

Name:

Job Title:

Email:

Company / Organization Details

Name:

Contact person:

Email:

Address:

City:

State / County:

Country:

Phone:

Payment Method

Please debit my

Mastercard Visa Amex Discover

Card Billing Address:

Street:

City / State: Post/Zip Code

Card Holder´s Name:

Card Holder´s Signature:

Card Number:

Visa CVC Number or Mastercard CVV Number or Amex DBC

3 or 4 digit code on the back or front of the card

Valid from Expiry Date

I agree to AL Conference Production Ltd. terms and Conditions and AL Conference Production Ltd. debiting my card.

Authorization and Acceptance of Sales Contract & Terms & ConditionsI hereby declare I am authorized to sign this contract and terms & conditions in the name of the company/organization:

Name:

Date:

Signature: Booking is invalid without a signature

Agreed Price of the Service

$ 1746Early Bird - 30% off per delegate

$ 2496

$ 3099

Industry Professional

Solution Provider

per delegate

per delegate